share_log

Virios Therapeutics Announces Initial FDA Feedback On Proposed IMC-1 Phase 3 Program For Treatment of Fibromyalgia; Says Final Toxicology Results To Be Submitted To FDA In May 2023

Benzinga ·  Apr 24, 2023 16:23
Virios Therapeutics Announces Initial FDA Feedback On Proposed IMC-1 Phase 3 Program For Treatment of Fibromyalgia; Says Final Toxicology Results To Be Submitted To FDA In May 2023
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment